Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7550153 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(1 year, 7 months from now) | |
US7553498 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(1 year, 7 months from now) | |
US7838027 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(1 year, 7 months from now) | |
US7550153
(Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(2 years from now) | |
US7553498
(Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(2 years from now) | |
US7838027
(Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Mar, 2025
(2 years from now) | |
US7544370 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Jun, 2026
(3 years from now) | |
US7544370
(Pediatric) | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Dec, 2026
(3 years from now) |
Market Authorisation Date: 14 November, 2007
Treatment: Erosive esophagitis, hypersecretory conditions including zollinger-ellison syndrome, maintenance of healing of erosive esophagitis and reduction of symptoms in patients with gerd
Dosage: FOR SUSPENSION, DELAYED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6780881
(Pediatric) | WYETH PHARMS | Freeze-dried pantoprazole preparation and pantoprazole injection |
May, 2022
(8 months ago) | |
US8754108
(Pediatric) | WYETH PHARMS | Freeze-dried pantoprazole preparation and pantoprazole injection |
May, 2022
(8 months ago) | |
US7351723
(Pediatric) | WYETH PHARMS | Freeze-dried pantoprazole preparation and pantoprazole injection |
May, 2022
(8 months ago) |
Market Authorisation Date: 22 March, 2001
Treatment: NA
Dosage: INJECTABLE;INTRAVENOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic